RFK Jr.’s vaccine panel weakens recommendation on hepatitis B shot for babies, scrapping universal guidance

RFK Jr.’s vaccine panel weakens recommendation on hepatitis B shot for babies, scrapping universal guidance


Dr. Vicky Pebsworth, from left, Massachusetts Institute of Technology professor Retsef Levi, Case Western Reserve University Professor Catherine Stein and Dr. Raymond Pollak, listen to presentations during an Advisory Committee on Immunization Practices (ACIP) meeting to discuss childhood vaccine schedule changes at the Centers for Disease Control and Prevention in Atlanta, Georgia, U.S., December 4, 2025.

Alyssa Pointer | Reuters

Health and Human Services Secretary Robert F. Kennedy Jr.’s hand-picked vaccine committee voted on Friday to do away with the long-standing, universal recommendation that all babies receive a hepatitis B shot at birth, issuing weaker guidance for certain infants.

The group, called the Advisory Committee on Immunization Practices, or ACIP, recommended that parents use individual decision-making in consultation with a health-care provider to determine when or if to give the hepatitis B birth dose to a baby whose mother tested negative for the virus. For babies who don’t receive the birth dose, the committee recommended that they wait to receive a first vaccine until they are at least 2 months old.

The acting director of the Centers for Disease Control and Prevention still has to sign off on that new recommendation. The CDC currently recommends that every baby get vaccinated against hepatitis B within 24 hours of birth, regardless of their mother’s testing status.

The move overturns that guidance, which has been credited with driving down infections in children by 99% since it was first introduced three decades ago and is widely considered to be a public health success story. Some members and public health experts warn that the change could have wide-ranging consequences, such as an increase in infections among kids.

Eight members voted yes, while three voted no. Some advisors strongly pushed back on the new guidance ahead of the vote.

“This has a great potential to cause harm, and I hope that the committee accepts the responsibility when this harm is caused,” said Dr. Joseph Hibbeln, psychiatrist and voting member.

Dr. Cody Meissner, a professor of pediatrics at the Dartmouth Geisel School of Medicine, said he hopes that pediatricians will continue to administer the birth dose within the first 24 hours of delivery and before discharge from the hospital.

“To follow any other course is not in the interest of infants,” he said.

Meissner added that more children will be injured and will catch hepatitis B infections. Hepatitis B, which can be passed from mother to baby during childbirth, can lead to liver disease and early death. Infants are more vulnerable to developing chronic hepatitis B infections, which have no cure.

“We will see hepatitis B come back,” he said. “The vaccine is so effective. It does not make sense in my mind to change the immunization schedule.”

A 2024 CDC study showed that the current vaccination schedule has helped prevent more than 6 million hepatitis B infections and nearly 1 million hepatitis B-related hospitalizations.

Merck and GSK manufacture the hepatitis B vaccines used starting at birth. Neither of the shots are significant revenue drivers for the companies, so the new recommendations should not have a material impact on their businesses.

This is breaking news. Please refresh for updates.



Source

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
Health

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit

The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]

Read More
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More